Collegium Pharmaceutical (COLL) Gains from Investment Securities (2024 - 2025)

Collegium Pharmaceutical's (COLL) quarterly Gains from Investment Securities came in at -$19000.0 in Q4 2025, up 99.35% year-on-year from -$9531.1 in Q4 2024, and little changed quarter-over-quarter from -$19000.0 in Q3 2025.

Collegium Pharmaceutical (COLL) Gains from Investment Securities (2024 - 2025) Analysis & Trends

Collegium Pharmaceutical's Gains from Investment Securities history runs 2 years deep, the most recent figure standing at -$19000.0 for Q4 2025.

  • On a quarterly basis, Gains from Investment Securities rose 99.35% year-over-year to -$19000.0 in Q4 2025; TTM through Mar 2026 was -$396000.0, a 89.3% increase from a year earlier, with the FY2025 full-year figure at -$1.2 million, up 59.44% from the prior year.
  • Gains from Investment Securities was little changed at -$19000.0 in Q4 2025 per COLL's latest filing, from -$19000.0 in the prior quarter.
  • Across five years, Gains from Investment Securities topped out at -$19000.0 in Q3 2025 and bottomed at -$2.9 million in Q4 2024.
Generated on {Timestamp} © BusinessQuant.com
Generated on {Timestamp} Powered by BusinessQuant Logo

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Haleon 87.22 Bn 85.35 Bn -
2 Teva Pharmaceutical Industries 39.60 Bn 35.87 Bn 1.97 Bn
3 Zoetis 31.46 Bn 29.52 Bn 1.62 Bn
4 Takeda Pharmaceutical 26.49 Bn 22.44 Bn 4.39 Bn
5 United Therapeutics 23.03 Bn 20.88 Bn 648.10 Mn
6 Universe Pharmaceuticals 23.03 Bn -10.56 Bn -
7 Viatris 20.90 Bn 19.09 Bn 1.16 Bn
8 Neurocrine Biosciences 17.50 Bn 16.19 Bn 800.70 Mn
9 Elanco Animal Health 12.33 Bn 11.91 Bn 785.00 Mn
10 Collegium Pharmaceutical 1.14 Bn 853.50 Mn 117.25 Mn

Historic Data

Download Data
DateValue
Dec 31, 2025 -19,000.00
Dec 31, 2025 -19,000.00
Sep 30, 2025 -19,000.00
Sep 30, 2025 -19,000.00
Jun 30, 2025 -358,000.00
Jun 30, 2025 -358,000.00
Mar 31, 2025 -786,000.00
Mar 31, 2025 -786,000.00
Dec 31, 2024 -2.91 Mn
Dec 31, 2024 -2.91 Mn